A study to evaluate safety and effectiveness of Rivaroxaban (Xarelto®) forPrevention of Stroke and Systemic Embolism in IndianPatients with Non-valvular Atrial Fibrillation (NVAF)

Phase 4

• Conditions: Health Condition 1: I489- Unspecified atrial fibrillation and atrial flutter

• Registration Number: CTRI/2019/09/021158
• Lead Sponsor: Bayer Zydus Pharma Private Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

• Patient should be an adult female or male, >=18 years of age;

• Patient should be diagnosed with NVAF and initiated with rivaroxaban treatment for

prevention of stroke or systemic embolism per investigatorâ??s routine treatment practice;

• Patient should not have received rivaroxaban in the past;

• Patient/patientâ??s legally acceptable representative should be willing to provide written

informed consent.

Exclusion Criteria

1. Patient has contraindications to receive rivaroxaban therapy according to local prescribing

information;

2. Patient is receiving anticoagulant therapy for indication other than NVAF and that needs to

be continued as per discretion of treating physician;

3. Patient is participating in an investigational program with interventions outside of routine

clinical practice.

Study & Design

• Study Type: Observational
• Study Design: Not specified